In Q3 of fiscal 2026, the quarter ended Oct 2, 2026, Exelixis, Inc. generated $280.0 million of cash from operations, down 3.6% from the same quarter a year earlier. It spent $2.5 million on capital expenditures. That left free cash flow of $277.5 million. The company returned $250.0 million in share buybacks to shareholders.
USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Oct 2, 2026
|
Q3 FY2026
Oct 2, 2026
|
Q2 FY2026
Jul 3, 2026
|
Q1 FY2026
Apr 3, 2026
|
Q4 FY2025
Jan 2, 2026
|
Q3 FY2025
Oct 3, 2025
|
Q2 FY2025
Jul 4, 2025
|
Q1 FY2025
Apr 4, 2025
|
Q4 FY2024
Jan 3, 2025
|
|---|---|---|---|---|---|---|---|---|---|
| Operating | |||||||||
| Depreciation and amortization |
28
-6.5%
|
7
-6.6%
|
7
-4.9%
|
7
-5.4%
|
7
-9.1%
|
7
-0.4%
|
7
+0.2%
|
7
+15.2%
|
8
+17.1%
|
| Stock-based compensation |
110
-7.4%
|
29
-7.0%
|
33
-9.7%
|
29
+12.0%
|
20
-23.7%
|
31
+34.1%
|
36
+42.3%
|
26
+35.7%
|
26
+8.4%
|
| Operating cash flow |
1,173
+48.3%
|
280
-3.6%
|
308
+528.1%
|
252
+19.1%
|
334
+38.8%
|
290
+7.0%
|
49
-59.0%
|
211
+207.2%
|
240
+2172.9%
|
| Investing | |||||||||
| Capital expenditures |
12
+6.4%
|
2
+67.9%
|
7
+140.2%
|
2
-48.9%
|
1
-70.9%
|
1
-81.9%
|
3
-56.8%
|
3
-69.5%
|
4
-69.7%
|
| Investing cash flow |
61
-73.5%
|
-7
-126.4%
|
91
-63.1%
|
-51
-202.6%
|
27
+129.2%
|
25
+111.7%
|
248
+203.3%
|
50
-55.5%
|
-93
-251.0%
|
| Financing | |||||||||
| Stock buybacks |
1,261
+43.2%
|
250
+140.3%
|
323
+7.0%
|
430
+51.6%
|
258
+35.3%
|
104
+772.3%
|
302
+14.2%
|
284
+53.2%
|
190
-9.0%
|
| Financing cash flow |
-1,305
-44.6%
|
-250
-140.6%
|
-344
-8.7%
|
-457
-55.0%
|
-255
-35.4%
|
-104
-1923.4%
|
-316
-20.5%
|
-295
-60.2%
|
-188
+8.8%
|
| Change in cash | |||||||||
| Net change in cash |
-72
-160.6%
|
23
-89.0%
|
55
+386.2%
|
-256
-662.4%
|
106
+359.2%
|
212
+253.8%
|
-19
+68.4%
|
-34
-879.4%
|
-41
+69.4%
|
| Free cash flow |
1,161
+48.9%
|
277
-3.9%
|
301
+552.0%
|
250
+20.1%
|
332
+40.7%
|
289
+9.8%
|
46
-59.1%
|
208
+252.6%
|
236
+9315.5%
|
| Per share | |||||||||
| Free cash flow per share |
4.38
+61.0%
|
1.08
+4.6%
|
1.16
+614.0%
|
0.94
+29.4%
|
1.20
+49.5%
|
1.04
+14.9%
|
0.16
-57.8%
|
0.72
+273.8%
|
0.80
+9921.5%
|
| Shareholder returns | |||||||||
| Returned to shareholders |
1,261
|
250
|
323
|
430
|
258
|
104
|
302
|
284
|
190
|
| Share of free cash flow |
108.60%
|
90.09%
|
107.33%
|
171.91%
|
77.51%
|
36.02%
|
654.15%
|
136.19%
|
80.59%
|
| Ratios | |||||||||
| Free cash flow margin |
46.50%
|
42.12%
|
47.87%
|
40.98%
|
55.52%
|
48.32%
|
8.12%
|
37.53%
|
41.69%
|
| Capital expenditures to revenue |
0.48%
|
0.38%
|
1.08%
|
0.25%
|
0.19%
|
0.25%
|
0.50%
|
0.53%
|
0.70%
|
| Stock-based compensation to revenue |
4.42%
|
4.36%
|
5.18%
|
4.76%
|
3.36%
|
5.17%
|
6.35%
|
4.67%
|
4.65%
|
| Cash conversion |
1.33x
|
1.28x
|
1.45x
|
1.20x
|
1.36x
|
1.50x
|
0.27x
|
1.32x
|
1.72x
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- EXEL (Nasdaq)
- Fiscal year ends
- January 1
- Incorporated in
- DE
- Headquarters
- Alameda, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 939767
- Former names
- EXELIXIS INC (until Sep 12, 2012)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Neurocrine Biosciences Inc NBIX
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.